SPEEDX
9.11.2020 14:02:13 CET | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive agreement to commercialise a host gene expression biomarker test for respiratory viral illness. Expression of the patented biomarker, IFI27, as discovered by NBMLHD Drs Anthony Maclean, Benjamin Tang and colleagues, is strongly correlated with disease progression in Influenza1 and COVID-19 patients2 . The commercial assay will be positioned to support clinicians facing difficult triage or patient management decisions, supporting risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005432/en/
“Host biomarkers are important indicators of a patient’s response to an infection,” said Professor Maclean, from the Nepean Hospital’s Intensive Care Unit. “Markers linked to viral specific immune responses, such as IFI27 – an interferon stimulating gene – are particularly informative. When they get switched on, it tells all the other immune cells to come and fight the virus. Levels of this specific marker, measured in the blood, have been shown to be directly correlated to progression of respiratory viral illness.”
The SpeeDx biomarker test utilises newly patented In SigniaTM technology that enhances the measurement of gene expression and is designed to run on standard laboratory equipment, allowing for expedited development and rapid adoption in high- and low-throughput hospital settings.
“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs. “Coupled with a pathogen detection assay and other disease indicators, this test can not only stratify patients based on risk of adverse disease progression, changes in the level of biomarker over time can inform more accurate prognoses and guide ongoing patient management decisions.”
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
References
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
- https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005432/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 07:30:00 CEST | Press release
Freedom Bank SuperApp to be promoted as a payment option on China’s leading e-commerce platforms through Antom On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allo
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ra
ATOZ Services Announces Strategic Growth Investment from Bregal Sagemount23.7.2026 06:30:00 CEST | Press release
Investment will support geographic expansion, AI investment and continued growth across ATOZ Services’ fund services platform ATOZ Services (The “Company”), an independent Luxembourg-based fund services platform, today announced that the Company will accelerate its strategic move to continue its international expansion and acquisition-based strategy through a growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm. Sagemount has entered into a partnership with ATOZ Group and ICG that will see Sagemount become the majority shareholder of the Company, while ATOZ Group and ICG retain a minority stake, subject to regulatory approval and other customary procedures. The investment will support the Company’s continued development as an international fund services platform. Founded in 2018 as part of the ATOZ Group, ATOZ Services provides fund-linked special purpose vehicle (“SPV”) services, fund administration, and fund governance, risk and complian
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom